EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

Siar Niazi iD, Filip Gnesin, Baker Nawfal Jawad, Zia Niazi, Puriya Daniel Wuertz Yazdanfard, Anne P Toft-Petersen, Kathrine Kold Sørensen, Amani Meaidi, Yousif Subhi iD, Christian Torp-Pedersen

Acta Ophthalmologica · 2026-12 · 104 (8)

DOI: 10.1111/aos.70168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Ophthalmologica, online erschienen am 13.05.2026. Verfasst von Siar Niazi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Optic Neuropathy, Ischemic, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nordsjællands Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration.

Methods

This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996–2023). Among 201 776 metformin‐treated adults initiating second‐line antihyperglycaemic therapy, 123 incident NAION cases were matched to 4920 controls by birth year and sex (incidence‐density sampling). Conditional logistic regression estimated adjusted hazard rate ratios (HRs) for GLP‐1RA exposure by recency (current 0–90 days; recent 91–365 days) and cumulative duration, adjusting for socio‐economic factors, hypertension, hypercholesterolaemia, sleep apnoea, and diabetes duration.

Results

GLP‐1RA use occurred in 63/123 cases (51.2%) and 1688/4920 controls (34.3%). Ever use was associated with a higher NAION rate than other second‐line therapies (HR 2.13, 95% CI: 1.43–3.18). Current use was associated with elevated rates (HR 2.28, 95% CI: 1.49–3.48), whereas the estimate for recent use was imprecise (HR 1.69, 95% CI: 0.88–3.25). By cumulative duration, no clear evidence of an increase was seen within 0–½ years (HR 0.80, 95% CI: 0.32–2.05), and rates were highest at ½–1 year (HR 3.63, 95% CI: 2.06–6.40) and 1–1½ years (HR 3.52, 95% CI: 1.73–7.17). Findings were consistent after HbA1c adjustment and in a new‐user analysis.

Conclusion

GLP‐1RA use is associated with a higher NAION rate in type 2 diabetes. This association appears time‐dependent, being most pronounced during current treatment and peaking after 6–18 months of cumulative exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Optic Neuropathy, IschemicGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansFemaleMaleDenmarkIncidenceMiddle AgedCase-Control StudiesTime FactorsRegistriesAgedRisk FactorsFollow-Up Studies

Stichwörter der Autor:innen

drug safetyglucagon‐like peptide‐1 receptor agonistsnonarteritic anterior ischaemic optic neuropathytype 2 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Steno Diabetes Center Copenhagen, Copenhagen University Hospital, Herlev, Denmark.
  • Department of Cardiology and Clinical Research, North Zealand Hospital, University of Copenhagen, Hillerød, Denmark.
  • Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Ear, Nose and Throat Head and Neck Surgery, Zealand University Hospital, Køge, Denmark.

ORCID-Profile: Siar Niazi, Yousif Subhi

Förderung

  • Nordsjællands Hospital

Zitieren

APA

Niazi, S., Gnesin, F., Jawad, B. N., Niazi, Z., Yazdanfard, P. D. W., Toft-Petersen, A. P., Sørensen, K. K., Meaidi, A., Subhi, Y., & Torp-Pedersen, C. (2026). Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy. Acta Ophthalmologica, 104(8). https://doi.org/10.1111/aos.70168

Vancouver

Niazi S, Gnesin F, Jawad BN, Niazi Z, Yazdanfard PDW, Toft-Petersen AP, et al. Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy. Acta Ophthalmologica. 2026;104(8). doi:10.1111/aos.70168

BibTeX
@article{Niazi2026,
  author = {Niazi, Siar and Gnesin, Filip and Jawad, Baker Nawfal and Niazi, Zia and Yazdanfard, Puriya Daniel Wuertz and Toft-Petersen, Anne P and Sørensen, Kathrine Kold and Meaidi, Amani and Subhi, Yousif and Torp-Pedersen, Christian},
  title = {Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy},
  journal = {Acta Ophthalmologica},
  year = {2026},
  volume = {104},
  number = {8},
  doi = {10.1111/aos.70168}
}
Kostenlos starten →